Tag:
biomarkers
Latest Headlines
Latest Headlines
Third Rock's Levin calls for teamwork in personalized medicine
Personalized medicine has the potential to revolutionize biotech and pharma, but only if stakeholders work together, Levin said.
Genomic Health, OncoMed to pursue companion diagnostics
Genomic Health and OncoMed Pharmaceuticals have an agreement to identify new biomarkers useful for future companion diagnostics that would go along with OncoMed's cancer drugs now in development.
Charles River and Metabolon partner to advance oncology research for others
What should one of the country's largest CROs do when it wants to beef up its work in oncology research? Call up Metabolon.
Tokai unveils promising Phase I data for 'triple whammy' prostate cancer contender
Cambridge, MA-based Tokai Pharmaceuticals presented a promising set of Phase I data pointing to the early efficacy of its "triple whammy" pill for castration-resistant prostate cancer.
Depression diagnostic passes initial trial
A test developed by Ridge Diagnostics appeared in an initial clinical trial to successfully differentiate between depressed and healthy patients. Massachusetts General Hospital researchers conducted
DVS Sciences lands $14.6M round with Big Pharma support
Big names in life sciences are backing DVS Sciences in a $14.6 million Series A round. With biomarker analysis technology for personalized medicine, the start-up has garnered investments from the
Roche, Evotec partner on oncology biomarkers
Roche announced it is tapping Evotec's PhosphoScout platform to discover protein activity-based biomarkers that predict dosing and efficacy of targeted cancer drugs. Over the next three years Roche
Amid politicized debate, Roche appeals Avastin choice
Roche has wasted no time in appealing the FDA's choice to revoke Avastin's breast cancer indication . The company asked for another public hearing at the agency, during which it can make a last-ditch
Data-sharing breeds Alzheimer's progress
A 2003 venture to bring together the NIH, FDA, industry, universities and nonprofits is paying dividends for Alzheimer's biomarker research. There have been advancements in using imaging for early
Biomarkers promise to revolutionize Alzheimer's research
A slate of new biomarkers developed to diagnose Alzheimer's at an early stage may revolutionize drug development work in the field. After years of study investigators have concluded that the dementia
